Antigen binding molecules against CD19 and methods thereof
Antigen binding molecules with specific CDR sequences enhance CD19 binding affinity, addressing the need for effective treatments for CD19-related disorders.
Patent Information
- Application Number
- PCT/IN2026/050835
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for CD19-related disorders, such as autoimmune diseases and B cell malignancies, lack antigen binding molecules with strong affinity for CD19.
Development of antigen binding molecules comprising specific variable heavy and light chain complementary determining regions (CDRs) with at least 70% sequence identity to predefined sequences, enhancing binding affinity to CD19.
The developed antigen binding molecules demonstrate improved binding to CD19, potentially offering effective treatments for CD19-mediated disorders.
Smart Images

Figure IMGF000008_0001_TABLE 
Figure IMGF000009_0001_TABLE 
Figure IMGF000010_0001_TABLE
Abstract
Description
“ANTIGEN BINDING MOLECULES AGAINST CD19 AND METHODS THEREOF”FIELD OF THE DISCLOSURE
[0001] The present disclosure relates to antigen binding molecules for binding to CD19, and compositions and methods thereof.BACKGROUND OF THE DISCLOSURE
[0002] CD 19 is a transmembrane glycoprotein predominantly expressed on the surface of B cells, where it plays an important role in B cell development, activation, and signalling. CD 19 is important for modulating immune responses, including both humoral immunity and immune tolerance.
[0003] CD19 consists of three parts: an extracellular domain to detect antigens; a transmembrane domain which anchors CD 19 in the cell membrane and an intracellular tail containing signalling motifs that help in activating B cell response.
[0004] CD 19 amplifies BCR signalling by acting as a co-receptor, lowering the activation threshold and increasing B cell sensitivity to antigens. Its intracellular tail contains immunoreceptor tyrosine -based activation motifs (ITAMs) that enhance BCR signalling, promoting B cell survival, growth, and antibody production. This cooperation ensures efficient immune activation and supports plasma and memory B cell formation.
[0005] Alterations in CD 19 lead to immunological disorders, such as autoimmune diseases, immune deficiencies, and B cell malignancies viz chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma. Due to its crucial role in B-cell signalling, CD 19 has become a target for B cell related disorders. Currently, there are CD 19 monoclonal antibodies that are approved for treatment of B cell cancers. However, there is still a need for binding molecules that can bind to CD 19 with a strong affinity. The present disclosure attempts to address this need. SUMMARY OF THE DISCLOSURE
[0006] The present disclosure provides an antigen binding molecule for binding to CD 19, wherein the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DZ1Z2TZ3TZ4WZ5PGAFDI (SEQ ID NO: 178), wherein Zi is F or L; Z2 is W or A; Z3 is I or P; Z4 is Q or T; Z5 is Y or T; or2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto; e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto .
[0007] In some embodiments, the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DFATPTTVVTPGAFDI (SEQ ID NO: 146); or. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto; e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto .
[0008] In some embodiments, the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DFATPTTVVTPGAFDI (SEQ ID NO: 147); or 2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto; e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto .
[0009] The present disclosure further provides an antigen binding molecule for binding to CD 19; wherein the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence selected from:- SYAX1X2 (SEQ ID NO: 1) or GYTFTX3Y (SEQ ID NO: 4), wherein Xi is I or M; X2 is S or H; and X3 is S or T; or- a sequence having at least 70% sequence identity thereto;b. a VH CDR2 having an amino acid sequence selected from:- X4IX5X6X7X8GX9X10X11YX12QKFQG (SEQ ID NO: 7), NPNSGN (SEQ ID NO: 11), or SAHSGD (SEQ ID NO: 12), wherein X4is W, R, or G; X5is N or I; X7, is A or P; X7 is G or I; Xs is N, L, or F; X9 is N, I, or T; X10 is T or A; Xu is K orN; and X12 is A or S; or- a sequence having at least 70% sequence identity thereto;c. a VH CDR3 having an amino acid sequence selected from:- DLAX13PX14 X42X43X44X45PX15X16FDI (SEQ ID NO: 13), VGWGFDY (SEQ ID NO: 15), LGLTGDGNRNY (SEQ ID NO: 16), QGY (SEQ ID NO: 17), or GGVYFYGMDV (SEQ ID NO: 18), wherein X13 is T or any other amino acid; X14 is T or any other amino acid; X42 is T or any other amino acid; X43 is V or any other amino acid; X44 is V or any other amino acid; X45 is T or any other amino acid; X15 is G or any other amino acid; Xi6 is A or any other amino acid; or- a sequence having at least 70% sequence identity thereto;d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence selected from:- X17ASQX18IDDDX19S (SEQ ID NO: 19), X20ASQX21IX22X23X24LX25 (SEQ ID NO: 22), or RSSQSLVHSDGNTYLS (SEQ ID NO: 25), wherein X17 is K or R; Xis is G or D; X19 is M or L; X20 is R or Q; X21 is G or D; X22 is S or H; X23 is S or M; X24 is A or F; X25 is A or S; or- a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence selected from:- EATX26LVP (SEQ ID NO: 26), DASX27LEX28 (SEQ ID NO: 29), or KVSNRDS (SEQ ID NO: 32), wherein X26is T or S; X27 is S or I; X28is S or A; or- a sequence having at least 70% sequence identity thereto; and f. a VL CDR3 having an amino acid sequence selected from:- LQHDNFPX29X30X31X32X33X34X35X36 (SEQ ID NO: 33), QQX37X38X39X40PX41T (SEQ ID NO: 36), MQGTQWPYT (SEQ ID NO: 39), wherein X29 is V or L; X30 is D or N; X31 is V or T; X32 is R or absent; X33 is P or absent; X34 is R or absent; X35 is D or absent; X36 is Q or absent; X37 is F or Y; X38 is N or D; X39 is S or N; X40 is F or I; X41 is L or G; or - a sequence having at least 70% sequence identity thereto.
[0010] The present disclosure also provides a pharmaceutical composition comprising the antigen binding molecule to CD 19 described herein.
[0011] In some embodiments, the present disclosure provides a kit comprising the antigen binding molecule or the pharmaceutical composition described herein, and a package insert or label providing instructions for administering the antigen binding molecule or the pharmaceutical composition to a subject.
[0012] The present disclosure also provides a method for treating a CD19-mediated disorder in a subject in need thereof, comprising administering to the subject the antigen binding molecule described herein or the pharmaceutical composition comprising them.
[0013] The present disclosure provides the antigen binding molecule, the pharmaceutical composition, or the kit described herein for use in treating a CD19-mediated disorder in a subject.BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 shows the results of ELISA screening of the scFv clones selected after biopanning.
[0015] Figure 2 shows the epitope-paratope interaction between CD19 and scFv 5_6_7.
[0016] Figure 3 shows the annotation of VH CDRs reflecting the designation mentioned in the epitope-paratope interaction shown in Figure 2.
[0017] Figure 4 shows the association and dissociation kinetic curves of scFv 5_6_7.
[0018] Figure 5 shows the association and dissociation kinetic curves of scFv 4_2_4.
[0019] Figure 6 shows the association and dissociation kinetic curves of scFv 7_7_6.
[0020] Figure 7 shows the association and dissociation kinetic curves of scFv 1_8_2.
[0021] Figure 8 shows the association and dissociation kinetic curves of scFv 3_5_1.DETAILED DESCRIPTION OF THE DISCLOSURE
[0022] With respect to the use of substantially any plural and / or singular terms herein, those having skill in the art can translate from the plural to the singular and / or from the singular to the plural as is appropriate to the context and / or application. The various singular / plural permutations may be expressly set forth herein for sake of clarity. The use of the expression “at least” or “at least one” suggests the use of one or more elements or ingredients or quantities, as the use may be in the embodiment of the disclosure to achieve one or more of the desired objects or results. Throughout this specification, the word “comprise”, or variations such as “comprises” or “comprising” or “containing” or “has” or “having”, or “including but not limited to” wherever used, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
[0023] Reference throughout this specification to “one embodiment”, “an embodiment”, or “some embodiments” means that a particular feature, structure or characteristic described in connection with the embodiment may be included in at least one embodiment of the present disclosure. Thus, the appearances of the phrases “in one embodiment”, “in an embodiment”, or “in some embodiments” in various places throughout this specification may not necessarily all refer to the same embodiment. It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosure, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination.
[0024] The present disclosure provides an antigen binding molecule that binds to human CD 19. As used herein, the term “antigen binding molecule” means a protein that comprises a portionthat binds to an antigen or a target protein. Examples of the representative types of antigen binding molecules include a single chain variable fragment (scFv), a full length antibody including a full length human antibody and fragments thereof; a bi-specific antibody, a tri-specific antibody; a scFv; a variable fragment (Fv); a Fab fragment; a Fab’ fragment; a F(ab')2 fragment; a humanized antibody; a chimeric antibody; a recombinant antibody; a nanobody; a diabody; a tribody; and a tetrabody. In some embodiments, the full-length antibody is an IgD antibody; an IgE antibody; an IgM antibody; an IgGl antibody; an IgG2 anti-body; an IgG3 antibody; or an IgG4 antibody. In some embodiments, the antigen binding molecule may comprise a scaffold or framework portion that allows the antigen binding portion to adopt a conformation that promotes binding of the antigen binding molecule to the antigen. Reference to an “affinity matured variant” encompasses a variant derived from a parent antibody and comprises one or more amino acid substitutions, insertions, or deletions, particularly within one or more complementarity-determining regions (CDRs) and / or framework regions, resulting in improved binding affinity to the target antigen.
[0025] An antigen binding molecule may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or they may be different. For example, a naturally occurring full-length antibody typically has two identical binding sites, while a "bispecific antibody" has two different binding sites, and is capable of specifically binding two different antigens.
[0026] As used herein, the term "percent identity" means the percent of identical residues between the amino acids or nucleotides in the compared molecules. In calculating percent identity, the sequences being compared are aligned in a way that gives the largest match between the sequences. For these calculations, gaps in alignments, if any, are generally addressed by a particular mathematical model or computer program. Several tools are available to determine percent identity between two sequences.
[0027] As used herein, each occurrence of X or Z in a sequence (including, but not limited to, Xi, X2, X3, ... and Zi, Z2, Z3, ... ) independently represents an amino acid residue selected from the group of amino acids specified for that position of the sequence in the present specification. Thus, unless otherwise indicated, each Xnor Znvariable may be independently selected from one or more amino acid residues as defined herein for the corresponding position, including conservative substitutions thereof. In the sequence listing, residues corresponding to Z positions are represented as X owing to technical constraints of the sequence listing tool.
[0028] The present disclosure provides an antigen binding molecule for binding to CD19. In some embodiments, the antigen binding molecule for binding to CD 19 comprises a variable heavy chain (VH) complementary determining region (CDR) 1, a VH CDR2, a VH CDR3, a variable light chain (VL) complementary determining region (CDR) 1 (VL CDR1), a VL CDR2, and a VL CDR3. The present disclosure provides CD 19 antigen binding molecules comprising specific CDR sequences as well as CDR sequences that show at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to them.
[0029] In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of the CD 19 antigen binding molecule of the present disclosure are selected from Table A below:Table ACDR SequencesVH CDR1 1. SYAX1X2 (SEQ ID NO: 1) wherein Xi is I or M and X2 is S or H:• SYAIS (SEQ ID NO: 2)• SYAMH (SEQ ID NO: 3)• SYAIH (SEQ ID NO: 50)• SYAMS (SEQ ID NO: 51)Few exemplary sequences showing at least 70% sequence identity:• TYAIS (SEQ ID NO: 52)• SYAIT (SEQ ID NO: 53)• SYAVS (SEQ ID NO: 54)• SYAMK (SEQ ID NO: 55)2. GYTFTX3Y (SEQ ID NO: 4) where X3is S or T:• GYTFTSY (SEQ ID NO: 5)• GYTFTTY (SEQ ID NO: 6)Few exemplary sequences showing at least 70% sequence identity:• GYSYTSY (SEQ ID NO: 56)• GYTFTSF (SEQ ID NO: 57)• GYTYTTY (SEQ ID NO: 58)• GYTFTTF (SEQ ID NO: 59)VH CDR2 1. X4IX5X6X7X8GX9X10X11YX12QKFQG (SEQ ID NO: 7), wherein X4 is W, R, or G; X5 is N or I; X7, is A or P; X7 is G or I;Xg is N, L, or F; X9 is N, I, or T; X10 is T or A; Xu is K orN; and X12 is A or S:• GIIPIFGTANYAQKFQG (SEQ ID NO: 8)• RIIPILGIANYAQKFQG (SEQ ID NO: 9)• WINAGNGNTKYSQKFQG (SEQ ID NO: 10)Few exemplary sequences showing at least 70% sequence identity:• GILPIFGSANYAQKFNG (SEQ ID NO: 60)• GLIPIYGTANYANKFQG (SEQ ID NO: 61)• KLIPILGIAQYANKFQG (SEQ ID NO: 62)• RIIPIIGIVNFAQKFQG (SEQ ID NO: 63)• YIQAGNGNSKYSNKFQG (SEQ ID NO: 64)• WINAGNGNSKYTQKFQG (SEQ ID NO: 65)2. NPNSGN (SEQ ID NO: 11)Few exemplary sequences showing at least 70% sequence identity:• NPNTGN (SEQ ID NO: 66)• QPNSGN (SEQ ID NO: 67)3. SAHSGD (SEQ ID NO: 12)Few exemplary sequences showing at least 70% sequence identity:• TAHSGD (SEQ ID NO: 68)• SAKSGD (SEQ ID NO: 69)VH CDR3 1. DLAX13PX14 X42X43X44X45PX15X16FDI (SEQ ID NO: 13) whereinX13 is T or any other amino acid; X14 is T or any other amino acid; X42 is T or any other amino acid; X43 is V or any other amino acid; X44 is V or any other amino acid; X45 is T or any other amino acid; X15 is G or any other amino acid; Xi6 is A or any other amino acid:• DLATPTTVVTPGAFDI (SEQ ID NO: 14)• DLATPTTIVTPGAFDI (SEQ ID NO: 136)• DLATPTHVTPGAFDI (SEQ ID NO: 137)• DLASPTTVVTPAGFDI (SEQ ID NO: 70)• DLATPSTVVTPAAFDI (SEQ ID NO: 71)Few exemplary sequences showing at least 70% sequence identity:• ELASPTTVVTPGAYDI (SEQ ID NO: 72)• DLVTPTTAVTPGAFEL (SEQ ID NO: 73)• DIATPTTVVSPGAFDI (SEQ ID NO: 74)• DFATPTTWTPGAFDI (SEQ ID NO: 146)• DLWTPTTVVTPGAFDI (SEQ ID NO: 147)• DLATITTVVTPGAFDI (SEQ ID NO: 148)• DLATPTQWTPGAFDI (SEQ ID NO: 149)• DLATPTTVVYPGAFDI (SEQ ID NO: 150)2. DZ1Z2TZ3TZ4VVZ5PGAFDI (SEQ ID NO: 178), wherein Zi is F or L; Z2 is W or A; Z3 is I or P; Z4 is Q or T; Z5 is Y or T:• DFATPTTWTPGAFDI (SEQ ID NO: 146)• DLWTPTTVVTPGAFDI (SEQ ID NO: 147)• DLATITTVVTPGAFDI (SEQ ID NO: 148)• DLATPTQWTPGAFDI (SEQ ID NO: 149)• DLATPTTVVYPGAFDI (SEQ ID NO: 150)3. DFATPTTWTPGAFDI (SEQ ID NO: 146)Few exemplary sequences showing at least 70% sequence identity:• DFATPTTVATPGAFDI (SEQ ID NO: 151)• DFATPTTWTPGAFEI (SEQ ID NO: 152)• DFATGTTWTPGAFDI (SEQ ID NO: 153)4. DLWTPTTVVTPGAFDI (SEQ ID NO: 147)Few exemplary sequences showing at least 70% sequence identity:• DLWTPTTVVTGGAFDI (SEQ ID NO: 154)• DLWTPSTVVTPGAFDI (SEQ ID NO: 155)• DLWTPTTVVTPGAVDI (SEQ ID NO: 156)5. DLATITTVVTPGAFDI (SEQ ID NO: 148)Few exemplary sequences showing at least 70% sequence identity:• ELATITTVVTPGAFDI (SEQ ID NO: 157)• DLATITTVLTPGAFDI (SEQ ID NO: 158)• DLATITTVVTPGAWDI (SEQ ID NO: 159)6. DLATPTQVVTPGAFDI (SEQ ID NO: 149)Few exemplary sequences showing at least 70% sequence identity:• DLATPTQWTPGAFEI (SEQ ID NO: 160)• DLATPTQWTGGAFDI (SEQ ID NO: 161)• DIATPTQVVTPGAFDI (SEQ ID NO: 162)7. DLATPTTVVYPGAFDI (SEQ ID NO: 150)Few exemplary sequences showing at least 70% sequence identity:• DLANPTTVVYPGAFDI (SEQ ID NO: 163)• ELATPTTVVYPGAFDI (SEQ ID NO: 164)• DLATPTTVVYPGAYDI (SEQ ID NO: 165)8. VGWGFDY (SEQ ID NO: 15)Few exemplary sequences showing at least 70% sequence identity:• AGWGFEY (SEQ ID NO: 75)• VGWGYDY (SEQ ID NO: 76)9. LGLTGDGNRNY (SEQ ID NO: 16)Few exemplary sequences showing at least 70% sequence identity:• LGLTGEGNHNY (SEQ ID NO : 77)• LGLSGEGNRQY (SEQ ID NO: 78)10. QGY (SEQ ID NO: 17)11. GGVYFYGMDV (SEQ ID NO: 18)Few exemplary sequences showing at least 70% sequence identity:• GGAYYYGMEV (SEQ ID NO: 79)• GGVYFYGMEI (SEQ ID NO: 80)VL CDR1 1. XI7ASQXI8IDDDXI9S (SEQ ID NO: 19)wherein X17 is K or R; Xis is G or D; X19 is M or L:• RASQDIDDDMS (SEQ ID NO: 20)• KASQGIDDDLS (SEQ ID NO: 21)• RASQGIDDDMS (SEQ ID NO: 81)• RASQGIDDDLS (SEQ ID NO: 82)• RASQDIDDDLS (SEQ ID NO: 83)• KASQDIDDDLS (SEQ ID NO: 84)• KASQGIDDDMS (SEQ ID NO: 85)• KASQDIDDDMS (SEQ ID NO: 86)Few exemplary sequences showing at least 70% sequence identity:• KASQEIDDDMS (SEQ ID NO: 87)• KASQEIDDEMS (SEQ ID NO: 88)• RATNDIDDDMS (SEQ ID NO: 89)• KASQGIDDEIS (SEQ ID NO: 90)• KASNGLDDDLS (SEQ ID NO: 91)• KASNGLEDDLS (SEQ ID NO: 92)2. KASQDIDDDMS (SEQ ID NO: 86)Few exemplary sequences showing at least 70% sequence identity:• LASQDIDDEMS (SEQ ID NO: 180)• KASQEIDDDAS (SEQ ID NO: 181)• KASCDYDDDMS (SEQ ID NO: 182)• KVTQDIDDDMS (SEQ ID NO: 183)3. X20ASQX21IX22X23X24LX25 (SEQ ID NO: 22) wherein X20 is R or Q; X21 is G or D; X22 is S or H; X23 is S or M; X24 is A or F; X25 is A or S:• RASQGISSALA (SEQ ID NO: 23)• QASQDIHMFLS (SEQ ID NO: 24)• RASQDISHALA (SEQ ID NO: 93)• RASQGISSFLA (SEQ ID NO: 94)• QASQDISSFLS (SEQ ID NO: 95)• QASQGIHMALS (SEQ ID NO: 96)Few exemplary sequences showing at least 70% sequence identity:• QASRGISTALA (SEQ ID NO: 97)• RASQGLSSAIA (SEQ ID NO: 98)• QASQEIHMFLT (SEQ ID NO: 99)• NASQEIHMYLS (SEQ ID NO: 100)• RASQDISHAIA (SEQ ID NO: 101)4. RSSQSLVHSDGNTYLS (SEQ ID NO: 25)Few exemplary sequences showing at least 70% sequence identity:• KSSQSLVKSDGQTYLS (SEQ ID NO: 102)• RSSQSIIHSDGNSYLS (SEQ ID NO: 103)• RSSNSLVHSEGNTYLS (SEQ ID NO: 104)VL CDR2 1. EATX26LVP (SEQ ID NO: 26) wherein X26is T or S:• EATTLVP (SEQ ID NO: 27)• EATSLVP (SEQ ID NO: 28)Few exemplary sequences showing at least 70% sequence identity:• DATTLIP (SEQ ID NO: 105)• EASSLVP (SEQ ID NO: 106)2. EATTLVP (SEQ ID NO: 27)Few exemplary sequences showing at least 70% sequence identity:• EMTTLLP (SEQ ID NO: 184)• ELTSLVP (SEQ ID NO: 185)• EAIVLVP (SEQ ID NO: 186)3. DASX27LEX28(SEQ ID NO: 29) wherein X27is S or I; X28is S or A:• DASSLES (SEQ ID NO: 30)• DASILEA (SEQ ID NO: 31)• DASSLEA (SEQ ID NO: 107)• DASILES (SEQ ID NO: 108)Few exemplary sequences showing at least 70% sequence identity:• EASSLDS (SEQ ID NO: 109)• DASSLET (SEQ ID NO: 110)• DASVLEA (SEQ ID NO: 111)• EATILEA (SEQ ID NO: 112)4. KVSNRDS (SEQ ID NO: 32)Few exemplary sequences showing at least 70% sequence identity:• KVSNRES (SEQ ID NO: 113)• RVSNQRDS (SEQ ID NO: 114)VL CDR3 1. LQHDNFPX29X30X31X32X33X34X35X36 (SEQ ID NO: 33) wherein X29 is V or L; X30 is D or N; X31 is V or T; X32 is R or absent; X33 is P or absent; X34 is R or absent; X35 is D or absent; X36 is Q or absent:• LQHDNFPVDVRPRDQ (SEQ ID NO: 34)• LQHDNFPLNT (SEQ ID NO: 35)• LQHDNFPLDVRPRDQ (SEQ ID NO: 115)• LQHDNFPVNVRPRDQ (SEQ ID NO: 116)• LQHDNFPVNTRPRDQ (SEQ ID NO: 117)• LQHDNFPVNT (SEQ ID NO: 118)• LQHDNFPLDT (SEQ ID NO: 119)• LQHDNFPLT (SEQ ID NO: 179)• LQHDNFPVNTV (SEQ ID NO: 120)Few exemplary sequences showing at least 70% sequence identity:• LNHENFPVDLRPRDQ (SEQ ID NO: 121)• LQHDNFPVDVRPKDN (SEQ ID NO: 122)• LNKDNFPLQT (SEQ ID NO: 123)• IQHDNFPLNS (SEQ ID NO: 124)2. LQHDNFPLT (SEQ ID NO: 179)• WQHDNFPVDT (SEQ ID NO: 187)• LQKDNFGLT (SEQ ID NO: 188)• LQHESFPLT (SEQ ID NO: 189)3. QQX37X38X39X40PX41T (SEQ ID NO: 36) wherein X37 is F or Y; X38 is N or D; X39 is S or N; X40 is F or I; X41 is L or G:• QQFNSFPLT (SEQ ID NO: 37)• QQYDNIPGT (SEQ ID NO: 38)• QQYNSFPGT (SEQ ID NO: 125)• QQFDSIPLT (SEQ ID NO: 126)• QQFDNFPLT (SEQ ID NO: 127)• QQFDNIPGT (SEQ ID NO: 128)• QQYDSIPGT (SEQ ID NO: 129)• QQYDNIPLT (SEQ ID NO: 130)Few exemplary sequences showing at least 70% sequence identity:• QQYNSFPIT (SEQ ID NO: 131)• NNFNSFPLT (SEQ ID NO: 132)• QQFNQSFPLT (SEQ ID NO: 133)• QQYENIPGS (SEQ ID NO: 134)• QRYENIPGT (SEQ ID NO: 135)4. MQGTQWPYT (SEQ ID NO: 39)Few exemplary sequences showing at least 70% sequence identity:• MQGTQWPFT (SEQ ID NO: 136)• YNGTQWPYT (SEQ ID NO: 137)
[0030] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DZ1Z2TZ3TZ4WZ5PGAFDI (SEQ ID NO: 178), wherein Zi is Phenylalanine (F) or Leucine (L); Z2 is Tryptophan (W) or Alanine (A); Z3 is Isoleucine (I) or Proline (P); Z4 is Glutamine (Q) or Threonine (T); Z5 is Tyrosine (Y) or Threonine (T); or2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto.
[0031] In some embodiments, the antigen binding molecule for binding to CD 19 comprises: antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of SYAIS (SEQ ID NO: 2);b. a VH CDR2 having an amino acid sequence of GIIPIFGTANYAQKFQG (SEQ ID NO: 8);c. a VH CDR3 having an amino acid sequence of DZ1Z2TZ3TZ4VVZ5PGAFDI (SEQ ID NO: 178), wherein Zi is F or L; Z2is W or A; Z3 is I or P; Z4 is Q or T; Z5 is Y or T;d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of KASQDIDDDMS (SEQ ID NO: 86); e. a VL CDR2 having an amino acid sequence of EATTLVP (SEQ ID NO:27); andf. a VL CDR3 having an amino acid sequence of LQHDNFPLT (SEQ ID NO: 179).
[0032] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DFATPTTVVTPGAFDI (SEQ ID NO: 146) or DLWTPTTWTPGAFDI (SEQ ID NO: 147); or 2. a sequence having at least 70% sequence identity thereto;d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto.
[0033] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DFATPTTVVTPGAFDI (SEQ ID NO: 146); or 2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto.
[0034] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DLWTPTTVVTPGAFDI (SEQ ID NO: 147); or 2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto.
[0035] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DLATITTVVTPGAFDI (SEQ ID NO: 148); or 2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto.
[0036] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DLATPTQVVTPGAFDI (SEQ ID NO: 149); or 2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto.
[0037] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DLATPTTVVYPGAFDI (SEQ ID NO: 150); or 2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or. a sequence having at least 70% sequence identity thereto.
[0038] In some embodiments, the antigen binding molecule for binding to CD 19 shows a CD 19 binding affinity ranging from about 2-30 nM. In some embodiments, the antigen binding molecule for binding to CD 19 shows a CD 19 binding affinity of about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 11 nM, about 12 nM, about 13 nM, about 14 nM, about 15 nM, about 16 nM, about 17 nM, about 18 nM, about 19 nM, about 20 nM, about 21 nM, about 22 nM, about 23 nM, about 24 nM, about 25 nM, about 26 nM, about 27 nM, about 28 nM, about 29 nM, or about 30 nM.
[0039] In some embodiments, the present antigen binding molecules exhibit a binding affinity to CD 19 of about 9 nM. In some embodiments, the present antigen binding molecules exhibit a binding affinity to CD19 of about 14.9 nM.
[0040] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DZ1Z2TZ3TZ4VVZ5PGAFDI (SEQ ID NO: 178), wherein Zi is F orL; Z2 is W or A; Z3 is I orP; Z4 is Q or T; Z5 is Y orT; or2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identity thereto,wherein the antigen binding molecule shows a CD 19 binding affinity ranging from about 2-30 nM.
[0041] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of:1. SYAIS (SEQ ID NO: 2); or2. a sequence having at least 70% sequence identity thereto; b. a VH CDR2 having an amino acid sequence of:1. GIIPIFGTANYAQKFQG (SEQ ID NO: 8); or2. a sequence having at least 70% sequence identity thereto; c. a VH CDR3 having an amino acid sequence of:1. DFATPTTVVTPGAFDI (SEQ ID NO: 146) or DLWTPTTWTPGAFDI (SEQ ID NO: 147); or 2. a sequence having at least 70% sequence identity thereto; d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of:1. KASQDIDDDMS (SEQ ID NO: 86); or2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence of:1. EATTLVP (SEQ ID NO: 27); or2. a sequence having at least 70% sequence identity thereto;andf. a VL CDR3 having an amino acid sequence of:1. LQHDNFPLT (SEQ ID NO: 179); or2. a sequence having at least 70% sequence identitythereto,wherein the antigen binding molecule shows a CD 19 binding affinity ranging from about 2-30 nM.
[0042] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of SYAX1X2 (SEQ ID NO: 1); b. the VH CDR2 having the amino acid sequence of X4IX5X6X7X8GX9X10X11YX12QKFQG (SEQ ID NO: 7);c. the VH CDR3 having the amino acid sequence of DLAX13PX14 X42X43X44X45PX15X16FDI (SEQ ID NO: 13);d. the VL CDR1 having the amino acid sequence of X17ASQX18IDDDX19S (SEQ ID NO: 19);e. the VL CDR2 having the amino acid sequence of EATX26LVP (SEQ ID NO: 26);andf. the VL CDR3 having the amino acid sequence of LQHDNFPX29X30X31X32X33X34X35X36 (SEQ ID NO: 33).
[0043] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of SYAX1X2 (SEQ ID NO: 1); b. the VH CDR2 having the amino acid sequence of X4IX5X6X7X8GX9X10X11YX12QKFQG (SEQ ID NO: 7);c. the VH CDR3 having the amino acid sequence of LGLTGDGNRNY (SEQ ID NO: 16);d. the VL CDR1 having the amino acid sequence of X17ASQX18IDDDX19S (SEQ ID NO: 19);e. the VL CDR2 having the amino acid sequence of EATX26LVP (SEQ ID NO: 26);andf. the VL CDR3 having the amino acid sequence of LQHDNFPX29X30X31X32X33X34X35X36 (SEQ ID NO: 33).
[0044] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of SYAX1X2 (SEQ ID NO: 1); b. the VH CDR2 having the amino acid sequence of X4IX5X6X7X8GX9X10X11YX12QKFQG (SEQ ID NO: 7);c. the VH CDR3 having the amino acid sequence of VGWGFDY (SEQ ID NO: 15);d. the VL CDR1 having the amino acid sequence of X20ASQX21IX22X23X24LX25 (SEQ ID NO: 22);e. the VL CDR2 having the amino acid sequence of DASX27LEX28 (SEQ ID NO:29); andf. the VL CDR3 having the amino acid sequence of QQX37X38X39X40PX41T (SEQ ID NO: 36).
[0045] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of GYTFTX3Y (SEQ ID NO: 4); b. the VH CDR2 having the amino acid sequence of NPNSGN (SEQ ID NO: 11); c. the VH CDR3 having the amino acid sequence of QGY (SEQ ID NO: 17); d. the VL CDR1 having the amino acid sequence of X20ASQX21IX22X23X24LX25 (SEQ ID NO: 22);e. the VL CDR2 having the amino acid sequence of DASX27LEX28 (SEQ ID NO:29); andf. the VL CDR3 having the amino acid sequence of QQX37X38X39X40PX41T (SEQ ID NO: 36).
[0046] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of GYTFTX3Y (SEQ ID NO: 4); b. the VH CDR2 having the amino acid sequence of SAHSGD (SEQ ID NO: 12); c. the VH CDR3 having the amino acid sequence of GGVYFYGMDV (SEQ ID NO:18);d. the VL CDR1 having the amino acid sequence of RSSQSLVHSDGNTYLS (SEQ ID NO: 25);e. the VL CDR2 having the amino acid sequence of KVSNRDS (SEQ ID NO: 32);andf. the VL CDR3 having the amino acid sequence of MQGTQWPYT (SEQ ID NO:39).
[0047] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of SY AIS (SEQ ID NO: 2); b. the VH CDR2 having the amino acid sequence of GIIPIFGTANYAQKFQG (SEQ ID NO: 8);c. the VH CDR3 having the amino acid sequence of DLATPTTVVTPGAFDI (SEQ ID NO: 14);d. the VL CDR1 having the amino acid sequence of RASQDIDDDMS (SEQ ID NO: 20);e. the VL CDR2 having the amino acid sequence of EATTLVP (SEQ ID NO: 27);andf. the VL CDR3 having the amino acid sequence of LQHDNFPVDVRPRDQ (SEQ ID NO: 34).
[0048] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of SYAMH (SEQ ID NO: 3); b. the VH CDR2 having the amino acid sequence of WINAGNGNTKYSQKFQG (SEQ ID NO: 10);c. the VH CDR3 having the amino acid sequence of LGLTGDGNRNY (SEQ ID NO: 16);d. the VL CDR1 having the amino acid sequence of KASQGIDDDLS (SEQ ID NO:21);e. the VL CDR2 having the amino acid sequence of EATSLVP (SEQ ID NO: 28);andf. the VL CDR3 having the amino acid sequence of LQHDNFPLNT (SEQ ID NO:35).
[0049] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of SY AIS (SEQ ID NO: 2); b. the VH CDR2 having the amino acid sequence of RIIPILGIANYAQKFQG (SEQ ID NO: 9);c. the VH CDR3 having the amino acid sequence of VGWGFDY (SEQ ID NO: 15); d. the VL CDR1 having the amino acid sequence of RASQGISSALA (SEQ ID NO:23);e. the VL CDR2 having the amino acid sequence of DASSLES (SEQ ID NO: 30);andf. the VL CDR3 having the amino acid sequence of QQFNSFPLT (SEQ ID NO:37).
[0050] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of GYTFTSY (SEQ ID NO: 5); b. the VH CDR2 having the amino acid sequence of NPNSGN (SEQ ID NO: 11); c. the VH CDR3 having the amino acid sequence of QGY (SEQ ID NO: 17);d. the VL CDR1 having the amino acid sequence of QASQDIHMFLS (SEQ ID NO: 24);e. the VL CDR2 having the amino acid sequence of DASILEA (SEQ ID NO: 31);andf. the VL CDR3 having the amino acid sequence of QQYDNIPGT (SEQ ID NO:38).
[0051] In some embodiments, the antigen binding molecule for binding to CD 19 comprises:a. the VH CDR1 having the amino acid sequence of GYTFTTY (SEQ ID NO: 6); b. the VH CDR2 having the amino acid sequence of SAHSGD (SEQ ID NO: 12); c. the VH CDR3 having the amino acid sequence of GGVYFYGMDV (SEQ ID NO:18);d. the VL CDR1 having the amino acid sequence of RSSQSLVHSDGNTYLS (SEQ ID NO: 25);e. the VL CDR2 having the amino acid sequence of KVSNRDS (SEQ ID NO: 32);andf. the VL CDR3 having the amino acid sequence of MQGTQWPYT (SEQ ID NO:39).
[0052] In some embodiments, a CDR sequence that is at least 70% identical to a reference VH or VL CDR sequence is provided; wherein the hydrophobic amino acid(s) in the reference sequence is replaced with another hydrophobic amino acid(s); polar amino acid(s) in the reference sequence is replaced with another polar amino acid(s); acidic amino acid(s) in the reference sequence is replaced with another acidic amino acid(s); basic amino acid(s) in the reference sequence is replaced with another basic amino acid(s) and the like. Table B below shows the exemplary classification of amino acids based on their nature.Table BNature of amino acids Amino acidsHydrophobic amino acids Met, Ala, Vai, Leu, He, Trp,Tyr, PhePolar neutral amino acids Cys, Ser, Thr, Gin, AsnAcidic amino acids Asp, GluBasic amino acids His, Lys, ArgSpecial amino acids Gly, Pro
[0053] The amino acids present in the same row can replace each other to provide variants with at least 70% sequence identity. For example, a Met residue can be replaced by an amino acid selected from Ala, Vai, Leu, He, Trp, Tyr, or Phe.
[0054] The VH, VL, SCFV, and full-length sequences having at least 70% sequence identity are provided in the similar manner. Although all such possible sequence variations may not be explicitly exemplified / disclosed here; CDR, VH, VL, scFv, and full-length sequences comprising these variations are contemplated and encompassed by the present disclosure.
[0055] In some embodiments, the antigen binding molecule for binding to CD19 comprises a VH chain having the amino acid sequence of: QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFG TANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDFATPTTVVTPGAF DIWGQGTMVTVSS (SEQ ID NO: 166).
[0056] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFG TANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDLWTPTTVVTPGA FDIWGQGTMVTVSS (SEQ ID NO: 167).
[0057] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFG TANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDLATITTVVTPGAF DIWGQGTMVTVSS (SEQ ID NO: 168).
[0058] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDLATPTQVVTPGA FDI (SEQ IDNO: 169).
[0059] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFG TANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDLATPTTVVYPGA FDIWGQGTMVTVSS (SEQ ID NO: 170).
[0060] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VL chain having the amino acid sequence of: ETTLTQSPLMSATPGDKVNISCKASQDIDDDMSWCQQKPGEAAIFTIQEATTLVPGISP RFSGSGYGTDFTLTINDIESEDAAYHFCLQHDNFPLTFGGGTKVEIKRTVAAPS (SEQ ID NO: 176).
[0061] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGT ANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDLATPTTVVTPGAFDI WGQGTMVTVSS (SEQ ID NO: 40).
[0062] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VL chain having the amino acid sequence of: ETTLTQSPLMSATPGDKVNISGRASQDIDDDMSWCQQKPGEAAIFTIQEATTLVPGISP RFSGSGYGTDFTLTINDIESEDAAYHFCLQHDNFPVDVRPRDQGGNQTCGRTRAHHH TTEIRLLTKPKRN (SEQ ID NO: 41).
[0063] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAG NGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARLGLTGDGNRNYW GQGTLVTVSS (SEQ ID NO: 42).
[0064] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VL chain having the amino acid sequence of: ETTLTQSPAFMSATPGHKVSLSCKASQGIDDDLSWYQQKPGEAVIFIIQEATSLVPGISPRFSGSGYGTDFTLTINNIESEDAAYYFCLQHDNFPLNTFGQGTKVEIKRAAALEHPP THPPTEIRLLTKPKRN (SEQ ID NO: 43).
[0065] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIA NYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVGWGFDYWGQGTLVTV SS (SEQ ID NO: 44).
[0066] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VL chain having the amino acid sequence of: DIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQRPGKAPRVLIYDASSLESGVP SRFSGSGSGTDFTLTISSLQPEDFATYSCQQFNSFPLTFGGGTKVEIKRAAALEHPTPPL RSGC (SEQ ID NO: 45).
[0067] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: QLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSG NTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARQGYWGQGTLVTVSS(SEQ ID NO: 46).
[0068] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VL chain having the amino acid sequence of: AIQMTQSPSSLSASVGDRVTITCQASQDIHMFLSWYQQTPGKAPRLLIYDASILEAGV ASRFSGSGSGKHFFFTITSLQPEDIATYYCQQYDNIPGTFGQGTKLEIKR (SEQ ID NO: 47).
[0069] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: QLVQSGGEVKKPGASVKVSCKTSGYTFTTYDVTWVRQAPGQGLEWMGWISAHSGD TKYSQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGVYFYGMDVWGQ GTTVTVSS (SEQ ID NO: 48).
[0070] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VL chain having the amino acid sequence of: DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSDGNTYLSWFQQRPGQSPRRLLYKVSNRDSGVPDRFSGSGSGTDFTLKISAMEAEDVGVYYCMQGTQWPYTFGQGTKLEIKR (SEQ ID NO: 49).
[0071] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having an amino acid sequence selected from: SEQ ID NOs: 166-170, 40, 42, 44, 46 and 48, or a sequence having at least 70% sequence identity thereto.
[0072] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having an amino acid sequence selected from: SEQ ID NOs: 166-170, or a sequence having at least 70% sequence identity thereto.
[0073] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VL chain having an amino acid sequence selected from: SEQ ID NOs: 176, 41, 43, 45, 47 and 49, or a sequence having at least 70% sequence identity thereto.
[0074] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VL chain having an amino acid of: SEQ ID NO: 176, or a sequence having at least 70% sequence identity thereto.
[0075] In some embodiments, the antigen binding molecule for binding to CD19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 166 and a VL chain having the amino acid sequence SEQ ID NO: 176.
[0076] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 167 and a VL chain having the amino acid sequence SEQ ID NO: 176.
[0077] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 168 and a VL chain having the amino acid sequence SEQ ID NO: 176.
[0078] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 169 and a VL chain having the amino acid sequence SEQ ID NO: 176.
[0079] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 170 and a VL chain having the amino acid sequence SEQ ID NO: 176.
[0080] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 40 and a VL chain having the amino acid sequence SEQ ID NO: 41.
[0081] In some embodiments, the antigen binding molecule for binding to CD19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 42 and a VL chain having the amino acid sequence SEQ ID NO: 43.
[0082] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 44 and a VL chain having the amino acid sequence SEQ ID NO: 45.
[0083] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 46 and a VL chain having the amino acid sequence SEQ ID NO: 47.
[0084] In some embodiments, the antigen binding molecule for binding to CD 19 comprises a VH chain having the amino acid sequence of: SEQ ID NO: 48 and a VL chain having the amino acid sequence SEQ ID NO: 49.
[0085] In some embodiments, the antigen binding molecule of the present disclosure binding to CD 19 is selected from a group comprising a full-length antibody and fragments thereof; a bi-specific antibody, a tri-specific antibody; a single chain variable fragment (scFv); a variable fragment (Fv); a Fab fragment; a Fab’ fragment; a F(ab')2 fragment; a nanobody; a diabody; a tribody; and a tetrabody.
[0086] In some embodiments, the antigen binding molecule of the present disclosure binding to CD19 is an scFv (also referred to herein as anti-CD19 scFV). In some embodiments, the anti-CD19 scFv does not comprise a linker between the VH and VL chains. In some embodiments, the anti-CD19 scFV comprises a linker between the VH and VL chains for example a peptide linker. The linker may be of any suitable length or composition sufficient to permit functional antigen binding. In a preferred embodiment, the linker has sequenceGGGGSGGGGSGGGGS (SEQ ID NO: 190). In some embodiments, the linker is Gly4-Ser linker. The VH and VL chains in the scFv may be arranged in any combination as envisaged by the above embodiments and in any orientation, including but not limited to a VH-VL orientation or a VL-VH orientation. The disclosure expressly contemplates scFvs comprising all permutations and arrangements of the VH and VL sequences disclosed herein.
[0087] In some embodiments, the antigen binding molecule of the present disclosure is a full-length human antibody. In some embodiments, the full-length human antibody binding to CD 19 is an IgG antibody such as an IgGl, IgG2, IgG3, or IgG4 antibody.
[0088] The antigen binding molecule of the present disclosure binds to CD 19. In some embodiments, the antigen binding molecule of the present disclosure exhibits a binding affinity of about 2 nM to 600 nM, including values and ranges thereof.
[0089] In some embodiments, the antigen binding molecule of the present disclosure exhibits a binding affinity of about 2 nM to 70 nM, including values and ranges thereof.
[0090] In some embodiments, the antigen binding molecule of the present disclosure exhibits a binding affinity of about 2 nM to 30 nM, including values and ranges thereof.
[0091] In some embodiments, the antigen binding molecule of the present disclosure exhibits a binding affinity of about 40 nM to 600 nM, including values and ranges thereof. In some embodiments, the present antigen binding molecules exhibit a binding affinity to CD 19 of about 40-550 nM, 40-500 nM, 40-450 nM, 40-400 nM, 40-450 nM, 40-300 nM, 40-250 nM, 40-200 nM, 40-170 nM, 40-150 nM, 40-100 nM, 40-80 nM, 60-600 nM, 60-550 nM, 60-500 nM, 60-450 nM, 60-400 nM, 60-350 nM, 60-300 nM, 60-250 nM, 60-200 nM, 60-180 nM, 100-600 nM, 100-550 nM, 100-500 nM, 100-450 nM, 100-400 nM, 100-300 nM, 150-600 nM, 150-500 nM, 150-400 nM, 150-300 nM, 150-200 nM, 200-600 nM, 200-500 nM, 200-400 nM, 250-600 nM, 250-500 nM, 250-450 nM, 300-600 nM, 300-550 nM, 300-500 nM, 400-600 nM, and the like. In some embodiments, the present antigen binding molecules exhibit a binding affinity to CD 19 of about 40-180 nM, including values and ranges thereof, such as about 40-70 nM, 40-80 nM, 40-100 nM, 40-140 nM, 40-160 nM, 80-160 nM, 100-160 nM, 150-180 nM, and the like.
[0092] In some embodiments, the present antigen binding molecules exhibit a binding affinity to CD 19 of about 60 nM. In some embodiments, the present antigen binding molecules exhibit a binding affinity to CD 19 of about 160 nM.
[0093] In some embodiments, the present disclosure provides polynucleotide sequences encoding the antigen binding molecules described herein. In some embodiments, provided herein are a polynucleotide sequence that encodes the VH amino acid sequence comprising SEQ ID NO: 166-170, 40, 42, 44, 46, or 48 and a polynucleotide sequence that encodes the VL amino acid sequence comprising SEQ ID NO: 176, 41, 43, 45, 47, or 49.
[0094] In some embodiments, provided herein are a polynucleotide sequence that encodes the VH amino acid sequence comprising SEQ ID NOs: 166-170 and a polynucleotide sequence that encodes the VL amino acid sequence comprising SEQ ID NO: 176.
[0095] In some embodiments, the polynucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 166 has the following sequence: CAAGTTCAACTCGTGCAAAGCGGCGCTGAAGTGAAAAAACCTGGTTCAAGCGTG AAGGTGAGCTGTAAAGCCTCCGGGGGCACATTCTCCAGCTACGCTATTAGCTGG GTCAGGCAGGCCCCTGGCCAGGGCCTCGAGTGGATGGGCGGCATAATCCCAATT TTCGGTACTGCTAACTACGCTCAGAAATTCCAAGGTAGAGTCACAATTACCGCTG ATGAATCCACATCAACTGCTTACATGGAACTCTCCTCCTTGCGGTCCGAAGATAC TGCCGTCTATTATTGTGCTAGGGACTTCGCAACCCCTACTACCGTGGTGACACCA GGGGCATTCGATATTTGGGGCCAGGGCACAATGGTGACAGTGTCTTCT (SEQ ID NO: 171).
[0096] In some embodiments, the polynucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 167 has the following sequence: CAAGTTCAACTCGTGCAAAGCGGCGCTGAAGTGAAAAAACCTGGTTCAAGCGTG AAGGTGAGCTGTAAAGCCTCCGGGGGCACATTCTCCAGCTACGCTATTAGCTGG GTCAGGCAGGCCCCTGGCCAGGGCCTCGAGTGGATGGGCGGCATAATCCCAATT TTCGGTACTGCTAACTACGCTCAGAAATTCCAAGGTAGAGTCACAATTACCGCTG ATGAATCCACATCAACTGCTTACATGGAACTCTCCTCCTTGCGGTCCGAAGATAC TGCCGTCTATTATTGTGCTAGGGACCTTTGGACCCCTACTACCGTGGTGACACCA GGGGCATTCGATATTTGGGGCCAGGGCACAATGGTGACAGTGTCTTCT (SEQ ID NO: 172).
[0097] In some embodiments, the polynucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 168 has the following sequence: CAAGTTCAACTCGTGCAAAGCGGCGCTGAAGTGAAAAAACCTGGTTCAAGCGTG AAGGTGAGCTGTAAAGCCTCCGGGGGCACATTCTCCAGCTACGCTATTAGCTGG GTCAGGCAGGCCCCTGGCCAGGGCCTCGAGTGGATGGGCGGCATAATCCCAATT TTCGGTACTGCTAACTACGCTCAGAAATTCCAAGGTAGAGTCACAATTACCGCTG ATGAATCCACATCAACTGCTTACATGGAACTCTCCTCCTTGCGGTCCGAAGATAC TGCCGTCTATTATTGTGCTAGGGACCTTGCAACCATCACTACCGTGGTGACACCA GGGGCATTCGATATTTGGGGCCAGGGCACAATGGTGACAGTGTCTTCT (SEQ ID NO: 173).
[0098] In some embodiments, the polynucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 169 has the following sequence: CAAGTTCAACTCGTGCAAAGCGGCGCTGAAGTGAAAAAACCTGGTTCAAGCGTG AAGGTGAGCTGTAAAGCCTCCGGGGGCACATTCTCCAGCTACGCTATTAGCTGG GTCAGGCAGGCCCCTGGCCAGGGCCTCGAGTGGATGGGCGGCATAATCCCAATT TTCGGTACTGCTAACTACGCTCAGAAATTCCAAGGTAGAGTCACAATTACCGCTG ATGAATCCACATCAACTGCTTACATGGAACTCTCCTCCTTGCGGTCCGAAGATAC TGCCGTCTATTATTGTGCTAGGGACCTTGCAACCCCTACTCAGGTGGTGACACCA GGGGCATTCGATATTTGGGGCCAGGGCACAATGGTGACAGTGTCTTCT (SEQ ID NO: 174).
[0099] In some embodiments, the polynucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 170 has the following sequence: CAAGTTCAACTCGTGCAAAGCGGCGCTGAAGTGAAAAAACCTGGTTCAAGCGTG AAGGTGAGCTGTAAAGCCTCCGGGGGCACATTCTCCAGCTACGCTATTAGCTGG GTCAGGCAGGCCCCTGGCCAGGGCCTCGAGTGGATGGGCGGCATAATCCCAATT TTCGGTACTGCTAACTACGCTCAGAAATTCCAAGGTAGAGTCACAATTACCGCTG ATGAATCCACATCAACTGCTTACATGGAACTCTCCTCCTTGCGGTCCGAAGATAC TGCCGTCTATTATTGTGCTAGGGACCTTGCAACCCCTACTACCGTGGTGTACCCA GGGGCATTCGATATTTGGGGCCAGGGCACAATGGTGACAGTGTCTTCT (SEQ ID NO: 175).
[0100] In some embodiments, the polynucleotide sequence encoding the VL amino acid sequence of SEQ ID NO: 176 has the following sequence:GAGACAACCCTGACCCAGTCCCCGCTAATGTCAGCAACTCCAGGCGATAAGGTT AACATCAGTTGCAAGGCATCACAGGACATAGACGACGATATGTCTTGGTGCCAG CAAAAACCCGGAGAAGCTGCCATTTTCACAATCCAGGAGGCCACTACCCTCGTTC CCGGGATCTCCCCACGATTCTCTGGCTCTGGATATGGCACAGACTTCACCCTGAC TATTAATGACATAGAGTCCGAGGATGCCGCCTACCACTTCTGTCTCCAACATGAC AACTTTCCTCTGACTTTCGGCGGTGGTACCAAGGTGGAGATCAAACGAACCGTGG CAGCTCCT (SEQ ID NO: 177).
[0101] In some embodiments, the polynucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 40 has the following sequence: CAGGTCCAGCTTGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTG AAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCT TTGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGG ACGAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACA CGGCCGTGTATTACTGTGCGAGAGATCTAGCTACCCCGACTACGGTGGTAACTCC CGGGGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCGAGT (SEQ ID NO: 138).
[0102] In some embodiments, the polynucleotide sequence encoding the VL amino acid sequence of SEQ ID NO: 41 has the following sequence: GAAACGACACTCACGCAGTCTCCACTCATGTCAGCGACTCCAGGGGACAAAGTC AACATCTCCGGCAGAGCCAGCCAAGACATTGATGATGATATGAGCTGGTGCCAA CAGAAACCAGGAGAAGCTGCTATCTTCACTATTCAAGAAGCAACTACTCTCGTTC CTGGAATCTCACCTCGCTTCAGTGGCAGCGGGTATGGAACAGATTTTACCCTCAC AATTAATGACATAGAATCTGAGGATGCTGCATATCACTTCTGTCTACAACATGAT AATTTCCCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGTGCGGC CGCACTCGAGCACACCACCACACCACTGAAATCCGGCTGCTAACAAAGCCCAAA CGGAAT (SEQ ID NO: 139).
[0103] In some embodiments, the polynucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 42 has the following sequence: CAGGTCCAGCTTGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTG AAGGTTTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGG TGCGCCAGGCCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAATATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGG ACACATCCGCGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACA CGGCTGTGTATTACTGTGCGAGATTGGGCCTAACTGGGGATGGGAATAGGAACT ACTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGT (SEQ ID NO: 140).
[0104] In some embodiments, the polynucleotide sequence encoding the VL amino acid sequence of SEQ ID NO: 43 has the following sequence: GAAACGACACTCACGCAGTCTCCAGCATTCATGTCAGCGACTCCAGGACACAAG GTCAGCCTCTCCTGCAAAGCCAGCCAAGGCATTGATGATGATTTGAGCTGGTACC AACAGAAACCAGGAGAAGCTGTTATTTTCATTATTCAAGAAGCTACTTCTCTCGT TCCTGGAATCTCACCTCGATTCAGTGGCAGCGGGTATGGAACAGATTTTACCCTC ACAATTAACAACATAGAATCTGAGGATGCTGCATATTACTTCTGTCTACAACATG ATAATTTCCCCCTGAACACTTTTGGCCAGGGGACCAAGGTGGAAATCAAACGT(SEQ ID NO: 141).
[0105] In some embodiments, the polynucleotide sequence encoding the VL amino acid sequence of SEQ ID NO: 44 has the following sequence:
[0106] In some embodiments, the polynucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 46 has the following sequence: CAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC TCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAACTGGGTGCGAC AGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAGTGGTA ACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCT CCATAAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCG TGTATTACTGTGCGAGACAAGGGTACTGGGGCCAGGGAACCCTGGTCACCGTCT CGAGT (SEQ ID NO: 142).
[0107] In some embodiments, the polynucleotide sequence encoding the VL amino acid sequence of SEQ ID NO: 47 has the following sequence: GCCATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCAGGCGAGTCAGGACATTCACATGTTTTTGAGTTGGTATCA GCAGACACCAGGGAAAGCCCCGAGACTCCTGATCTACGATGCATCCATTTTGGA AGCAGGGGTCGCATCAAGGTTCAGTGGAAGTGGATCTGGGAAACATTTTTTTTTC ACCATCACCAGCCTGCAGCCTGAAGATATCGCAACATACTACTGTCAACAATATGATAATATTCCGGGCACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGT (SEQ ID NO: 143).
[0108] In some embodiments, the polynucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 48 has the following sequence: CAGCTGGTGCAGTCTGGAGGTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC TCCTGTAAGACTTCTGGTTACACCTTTACCACCTACGATGTCACCTGGGTGCGAC AGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTCATAGTGGTG ACACAAAGTATTCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACAT CCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCG TGTATTACTGTGCGAGAGGTGGGGTCTACTTTTACGGTATGGACGTCTGGGGCCA AGGGACCACGGTCACCGTCTCGAGT (SEQ ID NO: 144).
[0109] In some embodiments, the polynucleotide sequence encoding the VL amino acid sequence of SEQ ID NO: 49 has the following sequence: GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGG CCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTACACAGTGATGGAAACACCTA CTTGAGTTGGTTTCAGCAGAGGCCAGGCCAATCTCCAAGGCGCCTACTTTATAAG GTTTCTAACCGGGACTCTGGGGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGC ACTGATTTCACACTGAAAATCAGCGCTATGGAGGCTGAAGATGTTGGGGTTTATT ACTGCATGCAAGGTACACAGTGGCCGTACACTTTTGGCCAGGGGACCAAGCTGG AGATCAAACGTGCGGCCGCACTCGAGCACCACACCACCACCACTGAGATCCGGC TGCTAACAAAGCCCGAAAGGAAACTGAATTGGCTGCTGCCACGCT (SEQ ID NO: 145).
[0110] In some embodiments, the antigen binding molecules comprise the above defined VH / VL sequences linked by a linker encoded by TCCGGAGGAGGTGGATCTGGCGGAGGCGGCAGTGGGGGCGGAGGTTCT (SEQ ID NO: 191).
[0111] In some embodiments, the polynucleotide sequences described herein are codon-optimized for expression in a eukaryotic cell such as a mammalian cell including a human cell, a Chinese hamster cell, a mouse cell, and the like.
[0112] In some embodiments, the polynucleotide sequences described herein are codon-optimized for expression in a prokaryotic cell such as bacterial cells or yeast.
[0113] The present disclosure also provides vectors comprising the polynucleotide sequence encoding the antigen binding molecules described herein. In some embodiments, the vector comprises the polynucleotide sequence encoding the VH amino acid sequence comprising SEQ ID NO: 166-170, 40, 42, 44, 46, or 48. In some embodiments, the vector comprises the polynucleotide sequence encoding the VL amino acid sequence comprising SEQ ID NO: 176, 41, 43, 45, 47, or 49.
[0114] In some embodiments, the vector comprises the polynucleotide sequence encoding the VH amino acid sequence comprising SEQ ID NO: 166-170. In some embodiments, the vector comprises the polynucleotide sequence encoding the VL amino acid sequence comprising SEQ ID NO: 176.
[0115] In some embodiments, the vector is a viral vector. In some embodiments, the vector is a retroviral vector, a DNA vector, a plasmid, a RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, an adenovirus associated vector (AAV), a lentiviral vector, or any combination thereof.
[0116] In some embodiments, the present disclosure provides a chimeric antigen receptor (CAR) comprising the antigen binding molecule described herein as an extracellular ligandbinding domain of the CAR. A CAR comprising the present antigen binding molecule as the extracellular ligand-binding domain would recognize and bind to CD 19. The CAR provided by the present disclosure comprises one or more components selected from a transmembrane domain, a hinge domain, an intracellular signalling domain, a co-stimulatory molecule and the like. The CAR provided by the present disclosure may be expressed in any immune cell. As used herein, the term “immune cell” refers to a cell of hematopoietic origin functionally involved in the initiation and / or execution of innate and / or adaptative immune response. Examples of immune cells that may be employed to express the CAR containing the antigen binding molecule of the present disclosure include T cells, e.g., alpha / beta T cells and gamma / delta T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, invariant NKT cells, mast cells, myeloic -derived phagocytes, dendritic cells, killer dendritic cells, macrophages, and monocytes.
[0117] The present disclosure also provides a pharmaceutical composition comprising the antigen binding molecule described herein and a pharmaceutically acceptable excipient. Insome embodiments, the pharmaceutically acceptable excipient is selected from a group comprising a carrier, a stabilizer, a buffer, a tonicity adjusting agent, a surfactant, an antioxidant, a chelating agent, and any combination thereof.
[0118] The present disclosure also provides a kit. In some embodiments, the kit comprises the antigen binding molecule described herein and a package insert or label providing instructions for administering the antigen binding molecule to a subject.
[0119] In some embodiments, the kit comprises the pharmaceutical composition comprising the antigen binding molecule of the present disclosure and a pharmaceutically acceptable excipient and a package insert or label providing instructions for administering the pharmaceutical composition to a subject.
[0120] The present disclosure also provides a method for treating a CD19-mediated disorder in a subject in need thereof, comprising administering to the subject the antigen binding molecule or the pharmaceutical composition of the present disclosure.
[0121] In some embodiments, the CD19-mediated disorder that is treated according to the present disclosure is a B-cell malignancy selected from B-cell leukemia and B-cell lymphoma. In some embodiments, the B-cell malignancy treated by the methods of the present disclosure is selected from acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-cell lymphomas such as non-Hodgkin lymphoma (NHL).
[0122] In some embodiments, the CD19-mediated disorder is an autoimmune disease. In some embodiments, the autoimmune disease treated by the methods of the present disclosure is selected from multiple sclerosis (MS), systemic lupus erythematosus (SLE), and myasthenia gravis (MG).
[0123] In some embodiments, the present disclosure provides the antigen binding molecule, the pharmaceutical composition, or the kit as described herein for use in treating a CD 19-mediated disorder in a subject. Exemplary CD- 19 mediated disorders are described above.
[0124] In some embodiments, the present disclosure provides use of the antigen binding molecule, the pharmaceutical composition, or the kit as described herein in treating a CD 19-mediated disorder in a subject. In some embodiments, the antigen binding molecules of the present disclosure can be used in various applications such as an extracellular ligand-bindingdomain of a chimeric antigen receptor (CAR) or for generating full-length antibodies for applications such as treatment of a CD19-mediated disorder, etc.
[0125] In some embodiments, the subject is an animal or a human.
[0126] It is to be understood that the foregoing descriptive matter is illustrative of the disclosure and not a limitation. While considerable emphasis has been placed herein on the particular features of this disclosure, it will be appreciated that various modifications can be made, and that many changes can be made in the preferred embodiments without departing from the principles of the disclosure. Those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein. Similarly, additional embodiments and features of the present disclosure will be apparent to one of ordinary skill in art based upon description provided herein.
[0127] Descriptions of well-known / conventional methods / steps and techniques are omitted so as to not unnecessarily obscure the embodiments herein. Further, the disclosure herein provides for examples illustrating the above-described embodiments, and in order to illustrate the embodiments of the present disclosure certain aspects have been employed. The examples used herein for such illustration are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skill in the art to practice the embodiments herein. Accordingly, the following examples should not be construed as limiting the scope of the embodiments herein.EXAMPLESExample 1: Generation of antigen binding molecules binding to CD19
[0128] A repertoire of variable heavy (VH) and variable light (VL) chains was generated from a germline B-cell and was used to construct single chain fragment variable (scFv) molecules. These scFvs were cloned into phages to generate a phage display library of scFvs. The phage display library was subjected to panning or biopanning where the library was screened using human CD19 protein with aHis Tag. Three different CD19 protein concentrations - 0.5 pg / mL, 1 pg / mL, and 1.5 pg / mL - were used in biopanning to select scFvs that showed highest binding / highest affinity to CD 19.
[0129] The scFvs that showed high binding affinity to CD 19 were selected. The binding of the selected scFvs was confirmed using ELISA.
[0130] For the ELISA assay, a buffer solution containing the antigen (CD 19) at a concentration of 250 ng / mL was added to the ELISA plate to coat CD 19 to the plate. After overnight incubation or incubation at 37°C for 2 hours, any unbound antigen was removed by washing the wells. A blocking buffer was added to the plates and incubated for 1 hour at 37°C. The bacteriophage supernatants were added to the antigen-coated, blocked wells. After incubation for 1.5-2 hours at room temperature, the wells were washed with a buffer. HRP- conjugated anti-M13 antibody was added to the wells and incubated for 1 hour. Unbound antibody was removed by washing the wells. A substrate solution was added to the wells and the absorbance was measured at 450 nm using a microplate reader. Figure 1 shows the result of the ELISA screening of the scFv clones selected after biopanning.
[0131] The scFv sequences selected from bioparming followed by ELISA were expressed in CHO cell line. Expressed scFvs were purified and were subjected to in vitro binding kinetics studies using Bio layer interferometer principle. Five clones showed efficient binding to CD19. The association and dissociation kinetic curves of five scFv clones are shown in Figures 4-8. The binding affinities of these 5 scFvs are summarized in Table 1 below.Table 1Sample Dissoc. Loading Affinity ID Loc. Loc. Ka(l / Ms) kdis (1 / s) KD (M) Response Dissoc RA2 (nM) scFv_5-6- 1.544E-7 plC4 plC2 2.580E05 02 5.986E-08 1.254 0.971136 59.8nM scFv_3-5- 7.995E- 1 plC4 plC2 4.990E04 03 1.602E-07 0.9956 0.997281 160nM scFv_7-7- 1.081E-6 plC4 plC2 2.300E04 02 4.702E-07 0.923 0.99374 470nM scFv_4-2- 6.054E-4 plC4 plC2 1.430E04 03 4.234E-07 0.1935 0.992664 423nM scFv_l-8- 9.294E-2 plC4 plC2 1.580E04 03 5.882E-07 0.6635 0.990207 588nMExample 2: Epitope-paratope interaction
[0132] A docking study was done between scFV 5_6_7 and CD 19 to see the paratope and epitope interaction using PyDock. Figure 2 shows the interaction between CD 19 and scFV 5 6 7. In Figure 2, chain A is a domain of CD19 while chain B is the VH chain of scFV 5 6 7.Example 3: Generation of affinity matured variants
[0133] Clone scFv_5-6-7 was subjected to affinity maturation and the following 5 affinity matured clones were selected and subjected to in vitro binding kinetics studies using Bio layer interferometer principle. The results of these studies are summarized in Table 2 below.Table 2Sample ID Vn CDRs VL CDRs Vn VL KD1 / 2 / 3 (SEQ 1 / 2 / 3 (SEQ (SEQ (nM) ID Nos.) (SEQ ID ID IDNos.) Nos.) Nos.)5-6-7_L251F 2 / 8 / 146 86 / 27 / 179 166 176 95-6-7_A252W 2 / 8 / 147 86 / 27 / 179 166 176 14.95-6-7 P254I 2 / 8 / 148 86 / 27 / 179 166 176 23.55-6-7 T256Q 2 / 8 / 149 86 / 27 / 179 166 176 3.85-6-7_T259Y 2 / 8 / 150 86 / 27 / 179 166 176 27
Claims
WE CLAIM:
1. An antigen binding molecule for binding to CD 19, wherein the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of SYAIS (SEQ ID NO: 2);b. a VH CDR2 having an amino acid sequence of GIIPIFGTANYAQKFQG (SEQ ID NO: 8);c. a VH CDR3 having an amino acid sequence of DZ1Z2TZ3TZ4WZ5PGAFDI (SEQ ID NO: 178), wherein Zi is F or L; Z2 is W or A; Z3 is I or P; Z4 is Q or T; Z5 is Y or T;d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of KASQDIDDDMS (SEQ ID NO: 86);e. a VL CDR2 having an amino acid sequence of EATTLVP (SEQ ID NO: 27); and f. a VL CDR3 having an amino acid sequence of LQHDNFPLT (SEQ ID NO: 179).
2. The antigen binding molecule for binding to CD 19 as claimed in claim 1, wherein the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of SYAIS (SEQ ID NO: 2);b. a VH CDR2 having an amino acid sequence of GIIPIFGTANYAQKFQG (SEQ ID NO: 8);c. a VH CDR3 having an amino acid sequence of: DFATPTTVVTPGAFDI (SEQ ID NO: 146);d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of KASQDIDDDMS (SEQ ID NO: 86);e. a VL CDR2 having an amino acid sequence of EATTLVP (SEQ ID NO: 27); and f. a VL CDR3 having an amino acid sequence of LQHDNFPLT (SEQ ID NO: 179).
3. The antigen binding molecule for binding to CD 19 as claimed in claim 1, wherein the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of SYAIS (SEQ ID NO: 2);b. a VH CDR2 having an amino acid sequence of GIIPIFGTANYAQKFQG (SEQ ID NO: 8);c. a VH CDR3 having an amino acid sequence of DLWTPTTVVTPGAFDI (SEQ ID NO: 147);d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of KASQDIDDDMS (SEQ ID NO: 86);e. a VL CDR2 having an amino acid sequence of EATTLVP (SEQ ID NO: 27); and f. a VL CDR3 having an amino acid sequence of LQHDNFPLT (SEQ ID NO: 179).
4. The antigen binding molecule for binding to CD 19 as claimed in claim 1, wherein the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of SYAIS (SEQ ID NO: 2);b. a VH CDR2 having an amino acid sequence of GIIPIFGTANYAQKFQG (SEQ ID NO: 8);c. a VH CDR3 having an amino acid sequence of DLATITTVVTPGAFDI (SEQ ID NO: 148);d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of KASQDIDDDMS (SEQ ID NO: 86);e. a VL CDR2 having an amino acid sequence of EATTLVP (SEQ ID NO: 27); and f. a VL CDR3 having an amino acid sequence of LQHDNFPLT (SEQ ID NO: 179).
5. The antigen binding molecule for binding to CD 19 as claimed in claim 1, wherein the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of SYAIS (SEQ ID NO: 2);b. a VH CDR2 having an amino acid sequence of GIIPIFGTANYAQKFQG (SEQ ID NO: 8);c. a VH CDR3 having an amino acid sequence of DLATPTQVVTPGAFDI (SEQ ID NO: 149);d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of KASQDIDDDMS (SEQ ID NO: 86);e. a VL CDR2 having an amino acid sequence of EATTLVP (SEQ ID NO: 27); and f. a VL CDR3 having an amino acid sequence of LQHDNFPLT (SEQ ID NO: 179).
6. The antigen binding molecule for binding to CD 19 as claimed in claim 1, wherein the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence of SYAIS (SEQ ID NO: 2);b. a VH CDR2 having an amino acid sequence of GIIPIFGTANYAQKFQG (SEQ ID NO: 8);c. a VH CDR3 having an amino acid sequence of DLATPTTWYPGAFDI (SEQ ID NO: 150);d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence of KASQDIDDDMS (SEQ ID NO: 86);e. a VL CDR2 having an amino acid sequence of EATTLVP (SEQ ID NO: 27); and f. a VL CDR3 having an amino acid sequence of LQHDNFPLT (SEQ ID NO: 179).
7. The antigen binding molecule as claimed in any one of claims 1-6, wherein the antigen binding molecule shows a CD 19 binding affinity ranging from about 2-30 nM.
8. An antigen binding molecule for binding to CD 19, wherein the antigen binding molecule comprises:a. a variable heavy chain (VH) complementary determining region (CDR) 1 having an amino acid sequence selected from:
1. SYAX1X2 (SEQ ID NO: 1) or GYTFTX3Y (SEQ ID NO: 4), wherein Xi is I or M; X2 is S or H; and X3 is S or T; or2. a sequence having at least 70% sequence identity thereto;b. a VH CDR2 having an amino acid sequence selected from:
1. X4IX5X6X7X8GX9X10X11YX12QKFQG (SEQ ID NO: 7), NPNSGN (SEQ ID NO: 11), or SAHSGD (SEQ ID NO: 12), wherein X4is W, R, or G; X5is N or I; X7, is A or P; X7 is G or I; Xg is N, L, or F; X9 is N, I, or T; X10 is T or A; Xu is K orN; and X12 is A or S; or2. a sequence having at least 70% sequence identity thereto;c. a VH CDR3 having an amino acid sequence selected from:
1. DLAX13PX14 X42X43X44X45PX15X16FDI (SEQ ID NO: 13), VGWGFDY (SEQ ID NO: 15), LGLTGDGNRNY (SEQ ID NO: 16), QGY (SEQ ID NO: 17), or GGVYFYGMDV (SEQ ID NO: 18), wherein X13 is T or any other amino acid; X14 is T or any other amino acid; X42 is T or any other amino acid; X43 is V or any other amino acid; X44 is V or any other amino acid; X45 is T or any other amino acid; X15 is G or any other amino acid; Xi6 is A or any other amino acid; or2. a sequence having at least 70% sequence identity thereto;d. a variable light chain (VL) complementary determining region (CDR) 1 having an amino acid sequence selected from:
1. XI7ASQXI8IDDDXI9S (SEQ ID NO: 19), X20ASQX21IX22X23X24LX25 (SEQ ID NO: 22), or RSSQSLVHSDGNTYLS (SEQ ID NO: 25), wherein X17 is K or R; Xi8is G or D; X19 is M or L; X20 is R or Q; X21 is G or D; X22 is S or H; X23 is S or M; X24 is A or F; X25 is A or S; or 2. a sequence having at least 70% sequence identity thereto;e. a VL CDR2 having an amino acid sequence selected from:
1. EATX26LVP (SEQ ID NO: 26), DASX27LEX28 (SEQ ID NO: 29), or KVSNRDS (SEQ ID NO: 32), wherein X26is T or S; X27is S or I; X28is S or A; or2. a sequence having at least 70% sequence identity thereto; and f. a VL CDR3 having an amino acid sequence selected from:
1. LQHDNFPX29X30X31X32X33X34X35X36 (SEQ ID NO: 33), QQX37X38X39X4oPX4iT (SEQ ID NO: 36), MQGTQWPYT (SEQ ID NO: 39), wherein X29 is V or L; X30 is D or N; X31 is V or T; X32 is R or absent; X33 is P or absent; X34 is R or absent; X35 is D or absent; X36 is Q or absent; X37 is F or Y; X?8is N or D; X39 is S or N; X40 is F or I; X41 is L or G; or2. a sequence having at least 70% sequence identity thereto.
9. The antigen binding molecule as claimed in claim 8, wherein the antigen binding molecule comprises:a. the VH CDR1 having the amino acid sequence of SYAX1X2 (SEQ ID NO: 1); b. the VH CDR2 having the amino acid sequence of X4IX5X6X7X8GX9XioXiiYXi2QKFQG (SEQ ID NO: 7);c. the VH CDR3 having the amino acid sequence of DLAX13PX14X42X43X44X45PX15X16FDI (SEQ ID NO: 13);d. the VL CDR1 having the amino acid sequence of XnASQXisIDDDXwS (SEQ ID NO: 19);e. the VL CDR2 having the amino acid sequence of EATX26LVP (SEQ ID NO: 26);andf. the VL CDR3 having the amino acid sequence of LQHDNFPX29X30X31X32X33X34X35X36 (SEQ ID NO: 33).
10. The antigen binding molecule as claimed in claim 8, wherein the antigen binding molecule comprises:g. the VH CDR1 having the amino acid sequence of SYAX1X2 (SEQ ID NO: 1); h. the VH CDR2 having the amino acid sequence of X4IX5X6X7X8GX9X10X11YX12QKFQG (SEQ ID NO: 7);i. the VH CDR3 having the amino acid sequence of LGLTGDGNRNY (SEQ ID NO: 16);j. the VL CDR1 having the amino acid sequence of X17ASQX18IDDDX19S (SEQ ID NO: 19);k. the VL CDR2 having the amino acid sequence of EATX26LVP (SEQ ID NO: 26);andl. the VL CDR3 having the amino acid sequence of LQHDNFPX29X30X31X32X33X34X35X36 (SEQ ID NO: 33).
11. The antigen binding molecule as claimed in claim 8, wherein the antigen binding molecule comprises:g. the VH CDR1 having the amino acid sequence of SYAX1X2 (SEQ ID NO: 1); h. the VH CDR2 having the amino acid sequence of X4IX5X6X7X8GX9X10X11YX12QKFQG (SEQ ID NO: 7);i. the VH CDR3 having the amino acid sequence of VGWGFDY (SEQ ID NO: 15); j . the VL CDR1 having the amino acid sequence of X20ASQX21IX22X23X24LX25 (SEQ ID NO: 22);k. the VL CDR2 having the amino acid sequence of DASX27LEX28 (SEQ ID NO:29); andl. the VL CDR3 having the amino acid sequence of QQX37X38X39X40PX41T (SEQ ID NO: 36).
12. The antigen binding molecule as claimed in claim 8, wherein the antigen binding molecule comprises:g. the VH CDR1 having the amino acid sequence of GYTFTX3Y (SEQ ID NO: 4); h. the VH CDR2 having the amino acid sequence of NPNSGN (SEQ ID NO: 11); i. the VH CDR3 having the amino acid sequence of QGY (SEQ ID NO: 17);j . the VL CDR1 having the amino acid sequence of X20ASQX21IX22X23X24LX25 (SEQ ID NO: 22);k. the VL CDR2 having the amino acid sequence of DASX27LEX28 (SEQ ID NO: 29); andl. the VL CDR3 having the amino acid sequence of QQX37X38X39X40PX41T (SEQ ID NO: 36).
13. The antigen binding molecule as claimed in claim 8, wherein the antigen binding molecule comprises:g. the VH CDR1 having the amino acid sequence of GYTFTX3Y (SEQ ID NO: 4); h. the VH CDR2 having the amino acid sequence of SAHSGD (SEQ ID NO: 12); i. the VH CDR3 having the amino acid sequence of GGVYFYGMDV (SEQ ID NO:18);j . the VL CDR1 having the amino acid sequence of RSSQSLVHSDGNTYLS (SEQ ID NO: 25);k. the VL CDR2 having the amino acid sequence of KVSNRDS (SEQ ID NO: 32);andl. the VL CDR3 having the amino acid sequence of MQGTQWPYT (SEQ ID NO:39).
14. The antigen binding molecule as claimed in claim 8 or 9, wherein the antigen binding molecule comprises:a. the VH CDR1 having the amino acid sequence of SYAIS (SEQ ID NO: 2); b. the VH CDR2 having the amino acid sequence of GIIPIFGTANYAQKFQG (SEQ ID NO: 8);c. the VH CDR3 having the amino acid sequence of DLATPTTVVTPGAFDI (SEQ ID NO: 14);d. the VL CDR1 having the amino acid sequence of RASQDIDDDMS (SEQ ID NO: 20);e. the VL CDR2 having the amino acid sequence of EATTLVP (SEQ ID NO: 27);andf. the VL CDR3 having the amino acid sequence of LQHDNFPVDVRPRDQ (SEQ ID NO: 34).
15. The antigen binding molecule as claimed in claim 8 or 10, wherein the antigen binding molecule comprises:g. the VH CDR1 having the amino acid sequence of SYAMH (SEQ ID NO: 3); h. the VH CDR2 having the amino acid sequence of WINAGNGNTKYSQKFQG (SEQ ID NO: 10);i. the VH CDR3 having the amino acid sequence of LGLTGDGNRNY (SEQ ID NO: 16);j . the VL CDR1 having the amino acid sequence of KASQGIDDDLS (SEQ ID NO:21);k. the VL CDR2 having the amino acid sequence of EATSLVP (SEQ ID NO: 28); andl. the VL CDR3 having the amino acid sequence of LQHDNFPLNT (SEQ ID NO:35).
16. The antigen binding molecule as claimed in claim 8 or 11, wherein the antigen binding molecule comprises:g. the VH CDR1 having the amino acid sequence of SYAIS (SEQ ID NO: 2); h. the VH CDR2 having the amino acid sequence of RIIPILGIANYAQKFQG (SEQ ID NO: 9);i. the VH CDR3 having the amino acid sequence of VGWGFDY (SEQ ID NO: 15); j . the VL CDR1 having the amino acid sequence of RASQGISSALA (SEQ ID NO:23);k. the VL CDR2 having the amino acid sequence of DASSLES (SEQ ID NO: 30);andl. the VL CDR3 having the amino acid sequence of QQFNSFPLT (SEQ ID NO: 37).
17. The antigen binding molecule as claimed in claim 8 or 12, wherein the antigen binding molecule comprises:g. the VH CDR1 having the amino acid sequence of GYTFTSY (SEQ ID NO: 5); h. the VH CDR2 having the amino acid sequence of NPNSGN (SEQ ID NO: 11); i. the VH CDR3 having the amino acid sequence of QGY (SEQ ID NO: 17);j . the VL CDR1 having the amino acid sequence of QASQDIHMFLS (SEQ ID NO:24);k. the VL CDR2 having the amino acid sequence of DASILEA (SEQ ID NO: 31);and1. the VL CDR3 having the amino acid sequence of QQYDNIPGT (SEQ ID NO: 38).
18. The antigen binding molecule as claimed in claim 8 or 13, wherein the antigen binding molecule comprises:g. the VH CDR1 having the amino acid sequence of GYTFTTY (SEQ ID NO: 6); h. the VH CDR2 having the amino acid sequence of SAHSGD (SEQ ID NO: 12); i. the VH CDR3 having the amino acid sequence of GGVYFYGMDV (SEQ ID NO:18);j . the VL CDR1 having the amino acid sequence of RSSQSLVHSDGNTYLS (SEQ ID NO: 25);k. the VL CDR2 having the amino acid sequence of KVSNRDS (SEQ ID NO: 32);andl. the VL CDR3 having the amino acid sequence of MQGTQWPYT (SEQ ID NO:39).
19. The antigen binding molecule as claimed in any one of claims 1-7, wherein the antigen binding molecule comprises a VH chain having an amino acid sequence selected from: SEQ ID NOs: 166-170, or a sequence having at least 70% sequence identity thereto.
20. The antigen binding molecule as claimed in any one of claims 1-7, wherein the antigen binding molecule comprises a VL chain having an amino acid sequence of SEQ ID NO: 176 or a sequence having at least 70% sequence identity thereto.
21. The antigen binding molecule as claimed in any one of claims 8-18, wherein the antigen binding molecule comprises a VH chain having an amino acid sequence selected from: SEQ ID NOs: 40, 42, 44, 46 and 48, or a sequence having at least 70% sequence identity thereto.
22. The antigen binding molecule as claimed in any one of claims 8-18, wherein the antigen binding molecule comprises a VL chain having an amino acid sequence selected from: SEQ ID NOs: 41, 43, 45, 47 and 49, or a sequence having at least 70% sequence identity thereto.
23. The antigen binding molecule as claimed in any one of claims 1-7, wherein the antigen binding molecule comprises:a. a VH chain having the amino acid sequence selected from SEQ ID NOs: 166-170 and a VL chain having the amino acid sequence of SEQ ID NO: 176.
24. The antigen binding molecule as claimed in any one of claims 8-18, 21 and 22 wherein the antigen binding molecule comprises:a. a VH chain having the amino acid sequence selected from SEQ ID NO: 40 and a VL chain having the amino acid sequence of SEQ ID NO: 41;b. a VH chain having the amino acid sequence of SEQ ID NO: 42 and a VL chain having the amino acid sequence of SEQ ID NO: 43;c. a VH chain having the amino acid sequence of SEQ ID NO: 44 and a VL chain having the amino acid sequence of SEQ ID NO: 45;d. a VH chain having the amino acid sequence of SEQ ID NO: 46 and a VL chain having the amino acid sequence of SEQ ID NO: 47; ore. a VH chain having the amino acid sequence of SEQ ID NO: 48 and a VL chain having the amino acid sequence of SEQ ID NO: 49.
25. The antigen binding molecule as claimed in any one of claims 8-18, 21-22 and 24, wherein the antigen binding molecule shows a CD 19 binding affinity of 40-600 nM.
26. The antigen binding molecule as claimed in any one of claims 1-25, wherein the antigen binding molecule is selected from a group comprising an scFv, an antibody or a fragment thereof, a nanobody, a bi-specific antibody, a tri-specific antibody, a Fab, a Fab', a Fv, and a F(ab')2.
27. The antigen binding molecule as claimed in any one of claims 1-7, wherein the antigen binding molecule comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, each having at least 70% sequence identity to the corresponding CDR sequence set forth in claims 1-6.
28. A pharmaceutical composition comprising the antigen binding molecule as claimed in any one of claims 1-27 and a pharmaceutically acceptable excipient.
29. The pharmaceutical composition as claimed in claim 28, wherein the pharmaceutically acceptable excipient is selected from a group comprising a carrier, a stabilizer, a buffer, atonicity adjusting agent, a surfactant, an anti-oxidant, a chelating agent, and any combination thereof.
30. A kit comprising the antigen binding molecule as claimed in any one of claims 1-27 or the pharmaceutical composition as claimed in claims 28 or 29, and a package insert or label providing instructions for administering the antigen binding molecule or the pharmaceutical composition to a subject.
31. A polynucleotide encoding the antigen binding molecule as claimed in any one of claims 1-27.
32. A vector comprising the polynucleotide as claimed in claim 31.
33. A method for treating a CD19-mediated disorder in a subject in need thereof, comprising administering to the subject the antigen binding molecule as claimed in any one of claims 1-27 or the pharmaceutical composition as claimed in claim 28 or 29.
34. The method as claimed in claim 33, wherein the CD19-mediated disorder is a B-cell malignancy selected from B-cell leukemia and B-cell lymphoma.
35. The method as claimed in claim 33, wherein the CD 19-mediated disorder is an autoimmune disease.
36. The antigen binding molecule as claimed in any one of claims 1-27, the pharmaceutical composition as claimed in claim 28 or 29, orthe kit as claimed in claim 30 for use in treating a CD 19-mediated disorder in a subject.
37. The antigen binding molecule as claimed in any one of claims 1-27, the pharmaceutical composition as claimed in claim 28 or 29, orthe kit as claimed in claim 30 for use in treating a B-cell malignancy selected from B-cell leukemia and B-cell lymphoma.
38. Use of the antigen binding molecule as claimed in any one of claims 1-27, the pharmaceutical composition as claimed in claim 28 or 29, orthe kit as claimed in claim 30 for treating a B-cell malignancy selected from B-cell leukemia and B-cell lymphoma.
39. The antigen binding as claimed in any one of claims 1-27, the pharmaceutical composition as claimed in claim 28 or 29, or the kit as claimed in claim 30 for use in treating anautoimmune disease selected from multiple sclerosis, systemic lupus erythematosus, and myasthenia gravis.
40. Use of the antigen binding molecule as claimed in any one of claims 1-27, the pharmaceutical composition as claimed in claim 28 or 29, or the kit as claimed in claim 30 for treating an autoimmune disease selected from multiple sclerosis, systemic lupus erythematosus, and myasthenia gravis .
41. The kit as claimed in claim 30, the method as recited in any one of claims 33-35, or the antigen binding molecule, pharmaceutical composition or kit for use as claimed in claim 36, wherein the subject is an animal or a human.
